- Previous Close
3,490.00 - Open
3,490.00 - Bid 3,410.00 x --
- Ask 3,440.00 x --
- Day's Range
3,410.00 - 3,520.00 - 52 Week Range
2,863.00 - 3,545.00 - Volume
30,400 - Avg. Volume
28,885 - Market Cap (intraday)
121.598B - Beta (5Y Monthly) --
- PE Ratio (TTM)
27.55 - EPS (TTM)
124.51 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield 80.00 (2.33%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
--
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension. In addition, the company provides Atelec to treat calcium channel blocker with a long-acting hypotensive effect; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Heparin Sodium MOCHIDA, an anticoagulant agent; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Dinagest, a therapeutic agent for endometriosis, adenomyosis, and dysmenorrhea. Further it offers skin care, baby care, personal care, and nursing products. Additionally, the company develops mesalazine, ethyl icosapentate, daridorexant, dotinurad, and treprostinil drugs for the treatment of ulcerative colitis, hypertriglyceridemia, insomnia, gout and hyperuricemia, and pulmonary hypertension associated with interstitial lung disease; and dMD-001, a medical device that is used for the treatment of articular cartilage lesions, as well as dMD-002, which is used for the treatment of cavernous nerve injury. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
www.mochida.co.jp1,522
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: 4534.T
View MorePerformance Overview: 4534.T
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4534.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4534.T
View MoreValuation Measures
Market Cap
121.60B
Enterprise Value
74.81B
Trailing P/E
27.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.18
Price/Book (mrq)
0.95
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
12.56
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
2.17%
Return on Equity (ttm)
3.46%
Revenue (ttm)
103.55B
Net Income Avi to Common (ttm)
4.41B
Diluted EPS (ttm)
124.51
Balance Sheet and Cash Flow
Total Cash (mrq)
49.73B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--